Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARN-509 with abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer
NL-OMON44408Active, not recruiting
- Sponsor
- Johnson & Johnson
- Start
- Oct 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of apalutamide, abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Johnson & Johnson. Primary endpoint: Effect of apalutamide on steady-state abiraterone pharmacokinetics. Started Oct 2014; status: active, not recruiting.
02
Drugs
apalutamideabirateroneprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON44408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44408.